These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 1886706)

  • 1. The 5' non-coding region of the BCR/ABL oncogene augments its ability to stimulate the growth of immature lymphoid cells.
    Gishizky ML; McLaughlin J; Pendergast AM; Witte ON
    Oncogene; 1991 Aug; 6(8):1299-306. PubMed ID: 1886706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABL oncogenes directly stimulate two distinct target cells in bone marrow from 5-fluorouracil-treated mice.
    Kelliher MA; Weckstein DJ; Knott AG; Wortis HH; Rosenberg N
    Oncogene; 1993 May; 8(5):1249-56. PubMed ID: 8479746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.
    Perrotti D; Bonatti S; Trotta R; Martinez R; Skorski T; Salomoni P; Grassilli E; Lozzo RV; Cooper DR; Calabretta B
    EMBO J; 1998 Aug; 17(15):4442-55. PubMed ID: 9687511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
    Guo JQ; Hirsch-Ginsberg CF; Xian YM; Stass SA; Champlin RE; Giralt SA; McCredie KB; Campbell ML; Arlinghaus RB
    Hematol Pathol; 1993; 7(2):91-106. PubMed ID: 8340287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
    Vaerman JL; Lewalle P; Martiat P
    Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia.
    Campanini F; Santucci MA; Pattachini L; Brusa G; Piccioli M; Barbieri E; Babini L; Tura S
    Haematologica; 2001 Feb; 86(2):167-73. PubMed ID: 11224486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
    Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional activation of human LIM-HOX gene hLH-2 in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
    Wu HK; Minden MD
    Biochem Biophys Res Commun; 1997 May; 234(3):742-7. PubMed ID: 9175786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.
    McLaughlin J; Chianese E; Witte ON
    Mol Cell Biol; 1989 May; 9(5):1866-74. PubMed ID: 2747638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New approach in the diagnosis and monitoring of treatment in chronic myelogenous leukemia].
    Matolcsy A
    Orv Hetil; 2004 Dec; 145(52):2603-9. PubMed ID: 15724695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
    Wu HK; Minden MD
    Biochem Biophys Res Commun; 1997 Apr; 233(3):806-12. PubMed ID: 9168938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
    Quackenbush RC; Reuther GW; Miller JP; Courtney KD; Pear WS; Pendergast AM
    Blood; 2000 May; 95(9):2913-21. PubMed ID: 10779439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.
    Kelliher M; Knott A; McLaughlin J; Witte ON; Rosenberg N
    Mol Cell Biol; 1991 Sep; 11(9):4710-6. PubMed ID: 1875948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines.
    Shah NP; Witte ON; Denny CT
    Mol Cell Biol; 1991 Apr; 11(4):1854-60. PubMed ID: 1900918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras.
    Sánchez-García I; Martín-Zanca D
    J Mol Biol; 1997 Mar; 267(2):225-8. PubMed ID: 9096220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.
    McLaughlin J; Chianese E; Witte ON
    Proc Natl Acad Sci U S A; 1987 Sep; 84(18):6558-62. PubMed ID: 3498165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABL oncogene expression during erythroleukemia cell differentiation.
    Leibowitz D; Popenoe D; Mears JG; Bank A; Schaefer-Rego K
    Leuk Res; 1991; 15(1):65-70. PubMed ID: 1997745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product.
    Castellanos A; Pintado B; Weruaga E; Arévalo R; López A; Orfao A; Sánchez-García I
    Blood; 1997 Sep; 90(6):2168-74. PubMed ID: 9310467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.